top of page
Incubate Responds to Maximum Fair Prices Announced for Next 15 Medicare Drugs
WASHINGTON ( November 26) -- Yesterday, the Trump administration announced Maximum Fair Prices (MFPs) for the next 15 Medicare Part D drugs selected for price setting under the Medicare Drug Price Negotiation Program. The new prices take effect in January 2027. Incubate's executive director, John Stanford, issued the following statement in response to the announcement: " Today's announcement is another reminder of the fundamental flaws in existing federal drug-pricing p
Incubate Coalition
Nov 26
Incubate Launches Life Sciences Rare Disease Tracker to Measure Research Setbacks Tied to U.S. Policy Environment
Incubate, a coalition of life sciences investors, today unveiled the Life Sciences Rare Disease Tracker , a tool designed to measure...
Incubate Coalition
May 15
Thomas Kaiser Talks Pill Penalty, North Carolina, and the Realities of Drug Development on Making Medicine
On the latest episode of the Making Medicine podcast, Incubate executive director John Stanford sat down with Thomas Kaiser of Avicenna...
Incubate Coalition
Apr 16
Incubate in PharmaVoice on Why Lawmakers Must Fix the Small Molecule Penalty
Incubate executive director John Stanford was recently featured in a PharmaVoice article by reporter Amy Baxter on proposed reforms to...
Incubate Coalition
Mar 17
Incubate in BioWorld on How the EPIC Act Would Restore Investment in Small Molecules
BioWorld regulatory editor Mari Serebrov recently interviewed Incubate's executive director John Stanford for her article on how the...
Incubate Coalition
Mar 11
Incubate in Endpoints News on the Importance of the EPIC Act
Incubate executive director John Stanford was recently featured in an Endpoints News article by senior editor Zachary Brennan on...
Incubate Coalition
Mar 11
Incubate applauds introduction of EPIC Act in the Senate
WASHINGTON, D.C. (March 5, 2025) -- This week, Senators Thom Tillis (R-NC), Ted Budd (R-NC), Marsha Blackburn (R-TN), James Lankford...
Incubate Coalition
Mar 5
Incubate Featured in STAT's Coverage of the EPIC Act Introduction
STAT reporter Ed Silverman recently interviewed Incubate's execute director John Stanford for an article on the EPIC Act's...
Incubate Coalition
Mar 5
Incubate Responds to Next 15 Drugs Selected for Medicare Price Controls
WASHINGTON (January 17) -- Today, the Centers for Medicare & Medicaid Services announced the second round of Medicare Part D drugs...
Incubate Coalition
Jan 17
Incubate Survey Finds That Drug Price Controls Create Headwinds for Life Sciences Startups
WASHINGTON ( January 13 ) -- Today, Incubate Policy Lab released insights from a survey of life sciences venture capital investors about...
Incubate Coalition
Jan 12
Looking back and looking ahead: A momentous (and misguided) time for drug pricing policy
August was a momentous month for the life sciences ecosystem, and September looks to be just as significant. In this blog post, we want...
Incubate Coalition
Sep 20, 2024
Incubate responds to Maximum Fair Prices for first 10 drugs selected for Medicare price controls
WASHINGTON (August 15) -- Today, the Biden administration announced Maximum Fair Prices (MFPs) for the first 10 drugs selected for...
Incubate Coalition
Aug 15, 2024
Incubate Launches Life Science Investment Tracker to Analyze Impact of the Inflation Reduction Act
WASHINGTON (June 13) -- Today, Incubate launched the Life Science Investment Tracker, a database monitoring changes in investment,...
Incubate Coalition
Jun 12, 2024
Incubate Submits Letter On HELP Committee Hearing
Incubate is an international coalition of life science venture capitalists committed to educating policymakers on the role of venture...
Incubate Coalition
Feb 7, 2024
Life Sciences Investors Applaud Bipartisan Bill To Eliminate Small-Molecule Penalty
This bipartisan legislation would eliminate the small-molecule penalty by aligning the price-setting timeline for small and large...
Incubate Coalition
Feb 1, 2024
bottom of page